I am Professor and Chair of Epidemiology at the department of Epidemiology, Erasmus MC Rotterdam, the Netherlands.
I am also adjunct professor of Epidemiology at the Harvard Chan School of Public Health.
And I am principal investigator of the Rotterdam Study and a key collaborator in the CHARGE (Cohorts for Heart and Aging Research in Genomic Epidemiology) consortium.
My research focuses on investigating:
- the etiology of dementia
- Alzheimer disease
- cognitive decline
The main areas
of research are to elucidate the earliest signs of brain diseases, before clinical symptoms are present, and to understand how these lead to clinical manifestation of disease. Moreover, I am interested in preclinical signs that can be used to identify persons at highest risk of developing disease.
To this aim I have used data from the large populationbased Rotterdam Study and Rotterdam Scan Study that have followed nearly 15,000 persons for a period of nearly 30 years.
An area of focus on my research has been the use of MRI-imaging to understand brain disease. Also, I have used neuropsychological testing, genome-wide, exome chip, DNA-methylation and sequencing technologies, and recently electronic gait assessments. Not only am I interested in how these pre-clinical markers lead to clinical disease, I also want to disentangle the intricate relationships between these markers.
Field(s) of expertise
Education and career
2003: MSc in Clinical Epidemiology
2005: MD degree
2009: PhD in Neuro-epidemiology
Previous studies in the lab have shown that autologous dendritic cells pulsed with allogenic tumor cell lysate was able to induce peripheral T cell activation and tumor-reactive T cell responses in patients with mesothelioma and pancreatic cancer. Current research focuses on how to initiate an effective immune response in the tumor as well as the tumor-draining lymph node using dendritic cell vaccination. Furthermore, we are studying novel approaches for (personalized) vaccination. In addition, we have identified T cell characteristics that underlie clinical efficacy of immune check inhibitors or chemotherapeutic agents in mesothelioma. The selected publications below give an impression of our work.
CE01: Clinical Translation of Epidemiology
EPI210 (Harvard): Study Design in Clinical Epidemiology